Who owns Catalent now?

Novo Holdings A/S completed its acquisition of Catalent on December 18, 2024, in an all-cash deal valuing the company at approximately $16.5 billion enterprise value, with shareholders paid $63.50 per share, a roughly 47.5% premium. CTLT was delisted from NYSE that day.

Is Catalent laying off workers in 2026?

Yes. Catalent cut about 350 jobs in Baltimore/Harmans, Maryland in August 2025, another 77 in November 2025, and 96 more in April 2026, all tied to gene therapy operations. It also announced closure of its Gosselies, Belgium cell-therapy site (about 150 jobs) in January 2026.

Who is Catalent's biggest competitor?

Lonza and Thermo Fisher are Catalent's largest rivals. Per Statista industry data as of 2024, Lonza generated about $8.14 billion in revenue and Thermo Fisher about $7 billion, versus Catalent's roughly $4.43 billion, meaning both larger CDMOs are pulling ahead of Catalent's scale.

Could AI replace Catalent's manufacturing business?

No. Catalent's core business is physical GMP-certified pharmaceutical manufacturing, which AI cannot replicate. On June 16, 2026, Catalent itself launched Qai, an internal AI tool built with Microsoft on Azure, aimed at speeding quality-assurance documentation and root-cause analysis, not replacing manufacturing staff.

Is Sarepta's Elevidys manufacturing at risk with Catalent?

There are warning signs. The FDA issued Form 483 findings on December 19, 2025 at Catalent's Maryland sites tied to Elevidys manufacturing, and Sarepta reportedly pushed batch deliveries to 2027 and beyond, though no formal contract termination has been confirmed as of mid-2026.

Is it safe to take a job at Catalent right now?

It is contested. Catalent has run four documented layoff rounds in roughly 12 months (Aug 2025 through April 2026) affecting Maryland gene therapy staff and closed its Belgium cell-therapy site, even as its core FDA-approved manufacturing sites remain a hard-to-replicate moat under new owner Novo Holdings.

Biotech tools companies · subsidiary of Novo Holdings A/S · United States

Catalent, Inc.

catalent.com ↗

CDMO making biologics, gene therapies, and drug-delivery for pharma clients, now owned by Novo Holdings.

Protection under test

Assessed 24 July 2026 · Evidence as of 24 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 24 July 2026 · Checkable from Q3-Q4 2026 · Every call on the record Checkpoint: Next Novo Holdings portfolio move or asset carve-out announcement

The call

Catalent keeps the regulatory footprint that keeps clients locked in, but four layoff rounds and site carve-outs since the Novo Holdings deal show a company being run for cash, not growth.

Catalent is a contract manufacturer that produces drugs and vaccines for pharmaceutical companies, handling everything from development through filling bottles and shipping. It has been hard to replace because it holds FDA approvals, certified facilities, and long-term contracts with customers, but competitors like Lonza and Thermo Fisher are now larger and growing while Catalent shrinks, losing customers and cutting staff by a fifth since 2023. The biggest question mark is whether its parent company Novo Nordisk will strip out more profitable sites to harvest cash, and whether delayed demand for gene therapies in Maryland will recover as promised.

Why

AI pressure: None apparent. AI tools speed up drug discovery and process design but don't replace physical GMP manufacturing capacity Catalent sells. Could AI do the core job? Unlikely.

Bigger players: Lonza, Thermo Fisher, Samsung Biologics. Bigger, better-funded CDMOs are winning new biologics and gene-therapy contracts while Catalent cuts staff and closes sites. Could a giant copy it? No, they are blocked.

What protects it. FDA-approved GMP sites and multi-year tech-transfer agreements are slow and costly for clients to move elsewhere.

What would change this call

Novo Holdings carves out another Catalent site to Novo Nordisk. Confirms Catalent is being run as a harvest asset, not a growth platform.
Further layoff rounds in Maryland or elsewhere beyond the ~427 already cut in 2025. Shows contraction is ongoing rather than stabilizing.
Sarepta/Elevidys batch deliveries resume or remain stalled through 2027. Indicates whether Catalent's Maryland gene-therapy demand is recovering or eroding further.

Key numbers

Novo Holdings bought Catalent for $16.5B enterprise value (2024-12-18)
Headcount fell 21%, from 15,700 to 12,350 (2025-12-31)
Novo Nordisk paid ~$11B for 3 fill-finish sites day one (2024-12-18)

Named risks

FDA Form 483 findings at Maryland sites tied to Elevidys manufacturing, Dec 19 2025. Severity: high
Four rounds of layoffs in 12 months (Aug 2025 to Apr 2026) signal ongoing contraction. Severity: high
Sarepta reportedly pushed Elevidys batch deliveries to 2027 and beyond. Severity: high
$78 million securities fraud settlement tied to 2021-2023 COVID-era accounting misstatements. Severity: medium
No public quarterly financials since going private Dec 2024, limiting outside visibility. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Lonza	gaining on	Lonza revenue ~$8.14B vs Catalent ~$4.43B in 2024, per Statista
Thermo Fisher Scientific	gaining on	Thermo Fisher CDMO revenue ~$7B in 2024, nearly double Catalent's
Samsung Biologics	gaining on	Samsung ~$3.3B revenue, expanding capacity, pursuing CDMO spin-off as of Jan 2026
WuXi Biologics	contesting	WuXi Biologics ~$2.6B revenue, named among top-5 CDMOs controlling 50-55% of market

Questions people ask

Who owns Catalent now?: Novo Holdings A/S completed its acquisition of Catalent on December 18, 2024, in an all-cash deal valuing the company at approximately $16.5 billion enterprise value, with shareholders paid $63.50 per share, a roughly 47.5% premium. CTLT was delisted from NYSE that day.
Is Catalent laying off workers in 2026?: Yes. Catalent cut about 350 jobs in Baltimore/Harmans, Maryland in August 2025, another 77 in November 2025, and 96 more in April 2026, all tied to gene therapy operations. It also announced closure of its Gosselies, Belgium cell-therapy site (about 150 jobs) in January 2026.
Who is Catalent's biggest competitor?: Lonza and Thermo Fisher are Catalent's largest rivals. Per Statista industry data as of 2024, Lonza generated about $8.14 billion in revenue and Thermo Fisher about $7 billion, versus Catalent's roughly $4.43 billion, meaning both larger CDMOs are pulling ahead of Catalent's scale.
Could AI replace Catalent's manufacturing business?: No. Catalent's core business is physical GMP-certified pharmaceutical manufacturing, which AI cannot replicate. On June 16, 2026, Catalent itself launched Qai, an internal AI tool built with Microsoft on Azure, aimed at speeding quality-assurance documentation and root-cause analysis, not replacing manufacturing staff.
Is Sarepta's Elevidys manufacturing at risk with Catalent?: There are warning signs. The FDA issued Form 483 findings on December 19, 2025 at Catalent's Maryland sites tied to Elevidys manufacturing, and Sarepta reportedly pushed batch deliveries to 2027 and beyond, though no formal contract termination has been confirmed as of mid-2026.
Is it safe to take a job at Catalent right now?: It is contested. Catalent has run four documented layoff rounds in roughly 12 months (Aug 2025 through April 2026) affecting Maryland gene therapy staff and closed its Belgium cell-therapy site, even as its core FDA-approved manufacturing sites remain a hard-to-replicate moat under new owner Novo Holdings.

Timeline

2026-06-16Launched Qai, first enterprise AI tool for quality management, built with Microsoft
2026-05-13Entered strategic partnership with Elpida Therapeutics for AAV gene therapy manufacturing
2026-04-19Cut 96 more jobs in Maryland via WARN notice
2026-01-26Announced closure of Gosselies, Belgium cell-therapy site, about 150 jobs
2025-12-29$78 million securities fraud class-action settlement preliminarily approved
2025-12-19FDA issued Form 483 findings at Maryland sites tied to Elevidys manufacturing
2025-11-06Cut 77 more jobs in Maryland gene therapy operations
2025-09-22Relocated global HQ to Tampa, Florida
2025-08-21Cut about 350 jobs in Baltimore/Harmans, Maryland
2024-12-18Novo Holdings completed $16.5B acquisition; Novo Nordisk bought 3 sites for ~$11B

Revision history

24 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Bio-Rad Laboratories Olympus Corporation Eppendorf AG